Detailed company information
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Aug 12, 2026
Earnings Transcript for 2026 - Q1Released: May 14, 2026
Earnings Transcript for 2025 - Q4Released: Mar 04, 2026
Earnings Transcript for 2025 - Q1Released: May 07, 2025
Earnings Transcript for 2024 - Q4Released: Feb 13, 2025
Earnings Transcript for 2024 - Q3Released: Oct 30, 2024
Earnings Transcript for 2024 - Q2Released: Aug 09, 2024
Earnings Transcript for 2024 - Q1Released: May 07, 2024
Earnings Transcript for 2023 - Q4Released: Feb 26, 2024
Earnings Transcript for 2023 - Q3Released: Nov 01, 2023
Earnings Transcript for 2023 - Q2Released: Aug 02, 2023
Earnings Transcript for 2023 - Q1Released: May 03, 2023
Earnings Transcript for 2022 - Q4Released: Feb 21, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 10, 2022
Earnings Transcript for 2022 - Q1Released: May 04, 2022
Earnings Transcript for 2021 - Q4Released: Feb 23, 2022
Earnings Transcript for 2021 - Q3Released: Nov 03, 2021
Earnings Transcript for 2021 - Q2Released: Aug 04, 2021
Earnings Transcript for 2021 - Q1Released: May 06, 2021
Earnings Transcript for 2020 - Q4Released: Feb 24, 2021
Earnings Transcript for 2020 - Q3Released: Nov 04, 2020
Earnings Transcript for 2020 - Q2Released: Aug 05, 2020
Earnings Transcript for 2020 - Q1Released: May 10, 2020
ANGO AngioDynamics, Inc.
STAAR Surgical's FY26 revenue cadence highlights stronger seasonal growth in China during 2H, driven by inventory normalization and new product launches, while the Americas maintain steady double-digit growth throughout the year.
Read post
Dafinchi
